Connect with us

Live Business Updates

Equity Analysts Lanthius Holdings, Inc. Let’s make predictions for Q3 2022 earnings (NASDAQ:LNTH)



businessnews logo

Lantheus Holdings, Inc. (NASDAQ: LNTH – GET RATINGS) — Investment analysts at B Riley released their Q3 2022 EPS estimates for Lantheus in a report released on Thursday, August 25th. B. Riley analyst Y. Zhi expects the medical device provider to earn $0.67 per share for the quarter. B. Riley has a “Buy” rating on the stock. The consensus estimate for Lantheus’ current full-year earnings is $3.35 per share. b. Riley reported Lantheus Q4 2022 earnings at $0.70 EPS, FY2022 earnings at $3.10 EPS, Q1 2023 earnings at $0.87 EPS, Q2 2023 earnings at $0.91 EPS, Q3 2023 earnings at $0.91 EPS, Q4 2023 earnings at $0.93 Released estimates on EPS and earnings for FY2023 at $3.69 EPS.

Several other analysts have weighed in on the stock. Truist Financial raised its target price on Lantheus shares from $77.00 to $94.00 in a research report on Monday, May 2. SVB Leerink raised its target price on Lantheus from $100.00 to $110.00 and gave the stock an “outperform” rating in a report on Friday, Aug.

Lantheus Trading down 5.9%

Shares of Lantheus opened Monday at $81.51. The firm’s 50-day moving average is $72.48 and its 200-day moving average is $61.67. The firm has a market capitalization of $5.60 billion, a PE ratio of 189.56 and a beta of 0.79. There is a 1-year low of $22.20 for Lantheus and a 1-year high of $86.85. The company has a current ratio of 1.85, a quick ratio of 1.69 and a debt-to-equity ratio of 0.27.

advertisement tradewins

Safest option in trades!

If you’re new to trading, you’ve probably heard the wrong thing about options—that they are risky, unpredictable, or difficult. And it couldn’t be more wrong! With Hughes Options Strategy, you will soon learn that the safest options for new accounts are the options themselves!

Lantheus (NASDAQ:LNTH – GET RATINGS) last announced its quarterly earnings data on Thursday, Aug. The medical device provider reported $0.81 EPS for the quarter, beating the consensus estimate of $0.64 by $0.17. Lantheus had a net margin of 4.88% and a return on equity of 28.88%. The business had revenue of $223.80 million during the quarter, compared to the consensus estimate of $204.51 million. During the same period last year, the business generated $0.11 earnings per share. The company’s revenue was up 121.4% on a year-on-year basis.

Hedge funds weigh in on Lantheus

Several hedge funds have recently bought and sold shares of LNTH. Vanguard Group Inc. increased its stake in Lantheus to 32.9% during the first quarter. Vanguard Group Inc. now owns 5,742,083 shares of the medical device provider’s stock worth $317,595,000 after purchasing an additional 1,422,269 shares last quarter. Lord Abbett & Company LLC purchased a new location in Lanthius for a value of $71,663,000 during the first quarter. Solius Capital Management LP increased its stake in Lantheus shares by 43.5% in the fourth quarter. Solius Capital Management LP now holds 1,764,627 shares of the medical device provider’s stock, valued at $50,980,000, after acquiring an additional 534,800 shares in the last quarter. Emerald Advisors LLC bought a new stake in Lantheus shares in the second quarter, valued at approximately $22,879,000. Finally, Deutsche Bank AG increased its position in Lantheus shares by 657.4% during the second quarter. Deutsche Bank AG now holds 380,910 shares of the medical device provider’s stock worth $25,152,000, after purchasing an additional 330,620 shares in the previous quarter. Institutional investors hold 97.14 per cent shares of the company.

Insider Buying and Selling in Lantheus

In other news, CAO Andrea Sabens sold 386 shares of Lenthius stock on Friday, July 15. Shares were sold at an average price of $69.12 for a total transaction of $26,680.32. Following the transaction, the chief accounting officer now owns 64,255 shares in the company, valued at $4,441,305.60. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, CAO Andrea Sabens sold 386 shares of the stock in a transaction on Friday, July 15. The stock was sold at an average price of $69.12 for a total value of $26,680.32. Following the completion of the sale, the Chief Accounting Officer now owns 64,255 shares of the company’s stock, valued at $4,441,305.60. The sale was disclosed in a legal filing with the SEC, which is available at this link. Additionally, CFO Robert J. Junior Marshall sold 5,000 shares of Lantheus stock in a transaction that occurred on Monday, August 15. The stock was sold at an average price of $82.82 for a total value of $414,100.00. Following the completion of the transaction, the Chief Financial Officer now directly owns 130,893 shares in the company, valued at $10,840,558.26. The disclosure of this sale can be found here. Over the past ninety days, insiders sold 8,751 shares of company stock for $700,218. 1.60% of the stock is currently owned by company insiders.

About Lantheus

(get rating)

Lantheus Holdings, Inc. develops, manufactures and commercializes diagnostic and therapeutic products that assist physicians in the diagnosis and treatment of heart, cancer and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound examinations of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; NeuroLight to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 for the detection of heart disease; and gallium-67 for the detection of various infections and cancerous tumors.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat to provide readers with the fastest and most accurate reporting. This story was reviewed by Marketbeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Before considering Lanthius, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and best-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified five stocks that top analysts are quietly whispering to their clients to buy before the broader market catches on… and Lantheus wasn’t on the list.

While Lanthius currently has a “buy” rating among analysts, top-rated analysts believe these five stocks to be the better buy.

Check out five stocks here




Spread the love
Click to comment

Leave a Reply

Your email address will not be published.